[Federal Register Volume 88, Number 164 (Friday, August 25, 2023)]
[Notices]
[Page 58281]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18369]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Award of a Single-Source Cooperative Agreement To Fund 
icddr,b (International Centre for Diarrhoeal Disease Research, 
Bangladesh)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), located 
within the Department of Health and Human Services (HHS), announces the 
award of approximately $6,000,000, for Year 1 funding to icddr,b. The 
award will support high quality public health research and surveillance 
activities to further strengthen the ability of the Government of 
Bangladesh and other global partners to detect, prevent, and respond to 
disease threats. Funding amounts for years 2-5 will be set at 
continuation.

DATES: The period for this award will be September 30, 2024 through 
September 29, 2029.

FOR FURTHER INFORMATION CONTACT: Lata Kumar, Global Health Center, 
Centers for Disease Control and Prevention, Atlanta, GA, 30033, 
Telephone: 404-639-7618, email: [email protected].

SUPPLEMENTARY INFORMATION: The single-source award will support high 
quality public health and implementation science research that will 
guide stakeholders to prioritize resources, develop policies, and 
implement practices and interventions that will help mitigate the 
impact of health threats on the Bangladeshi population and globally. 
icddr,b is in a unique position to conduct this work, as it is the only 
non-diplomatic partner that CDC is aware of that has the legal 
authority and operational expertise to process the import of laboratory 
supplies and reagents, including time sensitive reagents. Surveillance 
activities contemplated under this award detect and isolate high-
consequence pathogens whose handling and storage require advanced 
biocontainment skills and capacity. icddr,b's clinical microbiology 
laboratory meets the international standards of quality and is ISO 
15189-2012 accredited and the institute has a strong and active 
institutional biosafety committee and Senior Biosafety Officer. icddr,b 
is the most biosafety capable institution in the country to execute 
critical ongoing studies on pathogens having pandemic potential such as 
Nipah virus, the testing of human, avian and bovine surveillance 
samples with unknown etiology, and studies of C. auris and influenza. 
To CDC's knowledge, icddr,b is the only institution in Bangladesh with 
the capability to handle such pathogens according to international 
biosecurity standards. Furthermore, icddr,b has agreements with major 
biomedical transportation organizations and maintains a material 
transfer agreement (MTA) with CDC for the shipping of swabs, blood, 
serum and DNA.

Summary of the Award

    Recipient: icddr,b (International Centre for Diarrhoeal Disease 
Research, Bangladesh).
    Purpose of the Award: The purpose of this award is to further 
strengthen the ability of the Government of Bangladesh and other global 
partners to detect, prevent, and respond to disease threats through 
high quality public health research and surveillance activities. 
Specifically, the individual activities under this cooperative 
agreement will: (a) determine burden, trends, etiology, and risk 
factors of priority diseases in Bangladesh, (b) develop and evaluate 
interventions and diagnostics, (c) evaluate the effectiveness of 
vaccinations to inform global policy, and (d) strengthen the Government 
of Bangladesh's surveillance, laboratory, and outbreak response 
capacity.
    Amount of Award: The approximate year 1 funding amount will be 
$6,000,000 in Federal Fiscal Year (FY) 2024 funds, subject to the 
availability of funds. Funding amounts for years 2-5 will be set at 
continuation.
    Authority: This program is authorized under section 301(a) of the 
Public Health Service Act [42 U.S.C. 241(a)], as amended and section 
307 of the Public Health Service Act [42 U.S.C. 242l].
    Period of Performance: September 30, 2024 through September 29, 
2029.

    Dated: August 22, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 2023-18369 Filed 8-24-23; 8:45 am]
BILLING CODE 4163-18-P